1SIMPSON P T, REIS-FILHO J S, LAKHANI S R. Breast pathology: beyond morphology [ M ] . Semin Diagn Pathol, 2010, 27: 91-96.
2BEVERS T B, ANDERSON B O, BONACCIO E. NCCN clinical practice guidelines in oncology: breast Cancer screening and diagnosis [ J ] . J Natl Compr Cancer Netw, 2009, 7(10): 1060-1096.
3MANSEL R E, FALLOWFIELD L, KISSIN M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial [ J ] . J Natl Cancer Inst, 2006, 98: 599- 609.
4GOLDHIRSCH A, INGLE J N, GELBER R D, et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 [ J ] . Ann Oncol, 2009, 20: 1319-1329.
5American Joint Committee on Cancer. AJCC Cancer Staging Handbook [ M ] . 7th ed. Chicago: Springer, 2010.
6CARTER C L, ALLEN C, HENSON D E. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases [ J ] . CancerI, 1989, 63: 181-187.
7TAVASSOLI F A, DEVILEE P. World Health Organization Classification of Tumours// [ M ] . Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon, 2003.
8ELSTON C W, ELLIS I O. Pathological prognostic factors in breast cancer. I . The value of histological grade in breast cancer: experience from a large study with long-term follow- up [ J ] . Histopathology, 1991, 19: 403-410.
9FRIERSON H J JR, WOLBER R A, BEREAN K W, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma [ J ] . Am J Clin Pathol, 1995, 103: 195-198.
10KWOK T C, TAKHA E A, LEE A H, et al. Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation [ J ] . Histopathology, 2010, 57: 212-219.
2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
4Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
6Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
7Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
8Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
9Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.
10Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/ neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol,2002,118 (3) :408-417.
